Clinical Trial Update: Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing neratinib to lapatinib plus capecitabine in ErbB2-positive advanced breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)
• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Advanced Breast Cancer, Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-11-09